BrainStorm Appoints Prof. Jeffrey Kordower to its Scientific Advisory Board; World Renowned Neurologist and Specialist in Gene and Neural Transplantation to Provide Company Invaluable Guidance.TEL AVIV, Israel -- BrainStorm Cell Therapeutics (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :BCLI BCLI British Columbia Law Institute ), an emerging company in stem cell therapeutics for neurological diseases, today announced that Prof. Jeffrey Kordower, globally renowned neurologist scientist has joined the Company's Scientific Advisory Board, bringing a wealth of experience in gene therapy and neural transplantation.
Dr. Kordower presently holds a joint appointment at Rush Presbyterian-St. Luke's Medical Center as Professor of Neurosurgery neurosurgery /neu·ro·sur·gery/ (noor´o-sur?jer-e) surgery of the nervous system.
Surgery on any part of the nervous system. and the Jean Schweppe-Armour Professor of Neurological Sciences. He has previously held a number of appointments at Rush including, but not limited to, Director, Section on Neuroscience, Professor Neurological Science, Director, Research Center for Brain Repair and Adjunct Professor, Department of Anatomy and Biology.
In addition to his academic role, Prof. Kordower has acted as a consultant to biotech and pharmaceutical companies, including , among others, Lederle Labs, Cortex Pharmaceuticals, Cytrx, Regeneron, Cephalon, Amgen, Provirus provirus /pro·vi·rus/ (pro-vi´rus) the genome of an animal virus integrated (by crossing over) into the chromosome of the host cell, and thus replicated in all of its daughter cells. , Durect, Ceregene, Geron and Vertex Pharmaceuticals. He also advises the Food & Drug Administration and the Michael J. Fox Foundation, for Parkinson's Disease Research. Prof. Kordower is a member of the Society for Neuroscience For other uses, see SFN (disambiguation).
The Society for Neuroscience (SfN) is a professional society for basic scientists and physicians around the world whose research is focused on the study of the brain and nervous system. , New York Academy of Science, Cajal Club, American Association of Anatomists, American Association for the Advancement of Science American Association for the Advancement of Science (AAAS), private organization devoted to furthering the work of scientists and improving the effectiveness of science in the promotion of human welfare. , International Behavioral Neuroscience Society, American Society for Neural Transplantation and Repair and the Chicago Chapter of the Society for Neuroscience.
Prof. Kordower has made numerous international presentations, is a frequent invited lecturer and has authored over 150 publications, which have appeared in peer reviewed journals. He holds a Ph.D. in Neuropsychology neuropsychology
Science concerned with the integration of psychological observations on behaviour with neurological observations on the central nervous system (CNS), including the brain. from Queens College, C.U.N.Y. and did his Postdoctoral training at the University of Rochester The University of Rochester (UR) is a private, coeducational and nonsectarian research university located in Rochester, New York. The university is one of 62 elected members of the Association of American Universities. School of Medicine in Neurobiology Neurobiology
Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their and Anatomy.
"We are honored to welcome such an esteemed member of the neuroscience community to our Scientific Advisory Board. We are confident that his foresight and vision will assist Brainstorm to achieve its next stage of development," stated, Yaffa Beck, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. .
"The appointment of Prof. Ole Isacson and Prof. Jeffrey Kordower reinforce management and the Board's determination to forge ahead with our strategic objectives," Beck concluded.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like stem cell therapeutic products, NurOwn(TM), based on autologous autologous /au·tol·o·gous/ (aw-tol´ah-gus) related to self; belonging to the same organism.
1. bone marrow derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM) patent pending technology is based on discoveries made by the team of prominent neurologist, Prof. Eldad Melamed, Head of Neurology at Rabin Medical Center The Rabin Medical Center is a medical center in Petah Tikva, Israel. It is currently the second largest medical center in Israel after Sheba Medical Center, having lost the title of largest in 2006. , and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University, enabling the differentiation of bone marrow derived stem cells into functional neurons, as demonstrated in animal models. The company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Tel Aviv University (TAU, אוניברסיטת תל־אביב, את"א) is Israel's largest on-site university. Ltd., the technology transfer company of Tel Aviv University. The company's initial focus is on developing treatments for Parkinson's Disease.
About Stem Cell Therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs
Stem cells are non-specialized cells with a remarkable potential for both self-renewal and differentiation into cell types with a specialized function, such as muscle, blood or brain cells. Stem cells may be sourced from fetal or embryonic tissue or from adult tissue reservoirs such as bone marrow. Use of embryonic stem cells, has become the center of significant ethical and moral debate. In contrast, use of adult stem cells does not face the same moral or legal controversy. Stem cell therapy aims to "cure" disease by replacing the 'diseased' cells with 'healthy' cells derived from stem cells. This approach has the potential to revolutionize medicine and, if successful, the implied commercial opportunities are great. Currently, both embryonic stem cells (ESC See escape character and escape key. See also ESC/P.
ESC - escape ) and adult stem cells (ASC ASC Ambulatory surgery center, see there ) are being explored as the potential basis for multiple cell therapy products.
About Parkinson's Disease
Parkinson's Disease (PD), which was first described by James Parkinson in 1817 as "the shaking palsy," is a chronic, progressive neurodegenerative disorder, affecting the brain cells responsible for production of dopamine. The symptoms include tremors, rigidity, slowness of movement and impaired balance. Over four million people in the developed world, including as many as 1.5 million Americans, mainly over the age of 65, are diagnosed with PD. That figure is predicted to rise by 10% by 2010. Pharmaceutical treatments of PD with an estimated combined annual market value of $4 billion, are insufficient to meet patient needs. The search for more effective treatments continues.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc. actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc. limited operating history, history of losses and expectation to incur losses for the foreseeable future; need to raise additional capital to execute on its business plan; dependence on its license to Ramot's technology and ability to meet its funding and payment obligations included in such license agreement; ability, together with its licensor, to adequately protect the NurOwn(TM) technology; dependence on key executives who have recently joined the company and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc. market; the limited public trading market for BrainStorm Cell Therapeutics Inc. stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc. annual report on From 10-KSB, quarterly reports on Form 10-QSB, current reports on From 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company.